Milestone Pharmaceuticals Inc. (MIST) – What Are Brokerages Thinking About This Stock?

Shares of Milestone Pharmaceuticals Inc. (NASDAQ:MIST) have been assigned a consensus rating of “Moderate Buy” from the seven ratings firms that are covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, four have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month target price among brokers that have issued a report on the stock in the last year is $6.40.

Several brokerages recently weighed in on MIST. Zacks Research raised shares of Milestone Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Monday, July 13th. HC Wainwright reaffirmed a “buy” rating on shares of Milestone Pharmaceuticals in a research report on Thursday, September 3rd. Cantor Fitzgerald assumed coverage on Milestone Pharmaceuticals in a research report on Thursday, August 20th. They set an “overweight” rating and a $3.00 target price for the company. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Milestone Pharmaceuticals in a report on Monday, October 12th.

Institutional Investors Weigh In On Milestone Pharmaceuticals

A number of institutional investors have recently modified their holdings of MIST. HighTower Advisors LLC grew its holdings in Milestone Pharmaceuticals by 100.0% during the 2nd quarter. HighTower Advisors LLC now owns 20,000 shares of the company’s stock worth $27,000 after acquiring an additional 10,000 shares during the period. Welch & Forbes LLC bought a new position in shares of Milestone Pharmaceuticals in the 1st quarter worth about $30,000. Bay Rivers Group raised its position in shares of Milestone Pharmaceuticals by 55.9% in the 2nd quarter. Bay Rivers Group now owns 46,633 shares of the company’s stock worth $62,000 after acquiring an additional 16,722 shares in the last quarter. TRU Independence Asset Management 2 LLC acquired a new position in shares of Milestone Pharmaceuticals in the 4th quarter valued at about $202,000. Finally, ADAR1 Capital Management LLC acquired a new position in shares of Milestone Pharmaceuticals in the 2nd quarter valued at about $134,000. 86.18% of the stock is owned by institutional investors.

Milestone Pharmaceuticals Price Performance

NASDAQ:MIST opened at $0.72 on Friday. The company has a debt-to-equity ratio of 3.25, a quick ratio of 7.92 and a current ratio of 8.13. The stock’s 50-day moving average is $0.95 and its 200-day moving average is $1.28. Milestone Pharmaceuticals has a 1-year low of $0.70 and a 1-year high of $3.06.

Milestone Pharmaceuticals (NASDAQ:MIST) last announced its quarterly earnings results on Wednesday, August 12th. The company reported ($0.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by ($0.01). The business had revenue of $0.56 million for the quarter, compared to analysts’ expectations of $0.82 million. Sell-side analysts expect that Milestone Pharmaceuticals will post -0.84 earnings per share for the current year.

Milestone Pharmaceuticals Company Profile

Milestone Pharmaceuticals Inc is a biopharmaceutical company focused on developing and commercializing therapies for cardiovascular conditions. The company’s lead product candidate is etripamil, a short-acting calcium channel blocker formulated as a nasal spray and designed for rapid, patient-administered treatment.

Etripamil has been studied primarily for paroxysmal supraventricular tachycardia (PSVT), a condition characterized by episodes of abnormally rapid heart rate. The product is intended to provide patients with an option for treating episodes outside of a hospital or clinic, potentially reducing the need for emergency medical intervention.